A Phase 2 study of BA2101
Latest Information Update: 21 Feb 2024
At a glance
- Drugs BA 2101 (Primary)
- Indications Asthma; Atopic dermatitis; Pruritus; Sinusitis; Urticaria
- Focus Therapeutic Use
- 21 Feb 2024 New trial record
- 26 Jan 2024 According to a Shandong Boan Biotechnology media release, company has initiated a phase 2 clinical trial for BA2101.